Read more
Therapy Resistance in Prostate Cancer: Mechanisms and Insights, Volume 20highlights the main mechanisms that are responsible for therapy resistance in PCa allowing researchers and clinicians to have a synopsis of current options and therapies that can be proposed to overcome resistance. Understanding the mechanisms responsible for chemotherapy resistance helps researchers all over the world delve deeper into the pathways behind this resistance and potentially discover new therapeutic targets for PCa. Prostate cancer (PCa) is among the most diagnosed cancers in men worldwide, as well as one of the most common causes of cancer-related deaths. Despite the advances in treatment, the disease remains associated with poor survival and resistance to cytotoxic and targeted therapies.
List of contents
1. Prostate Gland Anatomy and Hormonal Factors Contributing to Cancer Development 2. Pathophysiology and Molecular Aberrations of Castration Resistant Prostate Cancer 3. Role of Tumor Microenvironment in Prostate Cancer Therapy Resistance 4. Androgen Receptor-Dependent Mechanisms Mediating Therapy Resistance in Prostate Cancer 5. Epigenetic Changes Driving Therapy Resistance in Prostate Cancer 6. Role of Cancer Stem Cells in Prostate Cancer Therapy Resistance 7. Resistance to Taxane Chemotherapies in Prostate Cancer 8. Resistance of Prostate Cancer to Topoisomerase Inhibitors 9. Resistance of Prostate Cancer to Kinase Inhibitors 10. Radioresistance Mechanisms in Prostate Cancer 11. Immunotherapeutic Strategies and Immunotherapy Resistance in Prostate Cancer 12. Overcoming Resistance in Prostate Cancer with Targeted and Small Molecule-Based Therapies 13. Novel Treatment Strategies to Overcome Resistance in Prostate Cancer
About the author
Dr. Bahmad is a physician scientist with more than 8 years of experience in basic, clinical, and translational research (2014-Present), mainly focusing on prostate, bladder, and brain tumors. His research work concentrates on understanding cancer progression and isolating and therapeutically targeting cancer stem cells in solid tumors (such as prostate cancer among others) which are believed to be responsible for therapy resistance and tumor recurrence. He has so far published more than 100 peer-reviewed papers and book chapters in well-reputable journals mainly related to cancer stem cells and overcoming therapy resistance in various tumors. Dr. Bahmad has an MBA degree in Healthcare Management from West Texas A&M University and is currently pursuing his Pathology Residency at Mount Sinai Medical Center of Florida.
